Biovica International Ab Class B · OMXSTO:BIOVIC_B
Biovica International Ab Class B — Q1 2024 Earnings Presentation
24 slides from Biovica International Ab Class B's earnings presentation, Sep 6, 2023
Slide 1: Q1 Interim Report FY23/24
Q1 Interim Report FY23/24 2023-09-06 1
Slide 2: Forward Looking-Statements Disclaimer
Forward Looking-Statements Disclaimer The Investor Presentation may contain certain statements that are forward-looking. These statements may refer in particular to the Company’s business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which
Slide 3: Q1 Interim Report Presenters
Q1 Interim Report Presenters Anders Rylander CEO Warren Cresswell President Biovica Americas Henrik Winther SVP Business Development Anders Morén CFO 3
Slide 4: Agenda
Agenda • Biovica introduction • Q1 Highlights • US Update • Pharma Services • Financial Update • Summary and Q&A 4 4
Slide 5: Biovica Overview
Biovica Overview • Founded 2009, based on research performed at Uppsala University • IPO 2017, traded on Nasdaq First North Premier • HQ in Uppsala, lab in San Diego • Regulatory: ISO 13485 certified • DiviTum® TKa CE labeled & FDA 510(k) cleared 5
Slide 6: DiviTum TKa Provides Early Response Indicator of Treatment Effectiveness
DiviTum® TKa Provides Early Response Indicator of the Effectiveness of Treatment For Cancer Patients Imaging diagnostics + Months DiviTum® TKa measures cell proliferation rate for faster evaluation of cancer treatment efficacy. References: http://biovica.com/technology/publications/ 6
Slide 7: Biovica Commercial Roadmap
Legend Biovica Commercial Roadmap 15% of market potential 50% of market potential MARKET POTENTIAL BREAST CANCER LAUNCHc BUILD REVENUES REALIZE POTENTIAL LAUNCHc BUILD REVENUES REALIZE POTENTIAL 400-700 LAUNCHc BUILD REVENUES REALIZE POTENTIAL METASTATIC mUSD/y LAUNCHc BUILD REVENUES REALIZE POTENTI
Slide 8: Q1 Significant Events
Q1 Significant Events 8
Slide 9: Q1 2023/2024 Highlights
Q1 2023/2024 Highlights Significant events during the Q1 May -July Extraordinary general meeting of Biovica International AB. Biovica signs its first commercial agreement in the USA with MediNcrease Health Plans. Results from the SWOG study (S0226) presented at ASCO. Biovica signs its second
Slide 10: US Business Update
US Business Update September 6th, 2023 10
Slide 11: We Continue to Execute the US Commercial Strategy
We Continue to Execute the US Commercial Strategy 1 Engagement and Feedback 2 Execute Client Bill (hospital) Contracting 3 Expand Commercial Agreement 4 Establish Coding, Pricing & Reimbursement 5 Expanding Clinical Utility in Breast Cancer 11
Slide 12: Engagement & Feedback Drives Demand
1 Engagement & Feedback Drives Demand Focused Engagement with Targeted Medical Oncologists, KOLs and Institutions 100% 35% We have ongoing engagement with We have conducted 525/1500 all NCI & NCCN designated cancer clinical presentations with targeted centers that treat patients Medical Oncologists
Slide 13: Execute Client Bill (hospital) Contracts
2 Execute Client Bill (hospital) Contracts Client Bill Contracts drive accelerated growth Focus: • Expands access to all oncologists at the institution o NCI Designated Institutions • Establishes ordering process at institutions o NCCN Designated Institutions o Notable Cancer Institutions • Guarante
Slide 14: Expand Commercial Agreements
3 Expand Commercial Agreements We have executed a 3rd commercial agreement with Occum Health (July 2023) Provide solutions to self insured employers for services performed by out of network providers Establish pre-negotiated rates for covered services Enable reimbursement of DiviTum® by affili
Slide 15: Establish Coding, Pricing & Reimbursement
4 Establish Coding, Pricing & Reimbursement Coding and Pricing: Enables payment from Medicare Medicare credentialling (Mar 2023) PLA code is specific to DiviTum being run in our AMA PLA code approved (Jul 2023) San Diego CLIA lab • CMS preliminary recommendation (Sep/Oct) Crosswalk or Gapfill Re
Slide 16: Expanding Clinical Utility in Breast Cancer
5 Expanding Clinical Utility in Breast Cancer Interventional Trials Observational Trials Yale Trial WashU – Impact Trial Drug to drug interaction and dose reduction Real time biomarker of tumor response to CDK4/6 inhibition in HR+ metastatic breast cancer New Trials in Discussion New Trials in Discu
Slide 17: Pharma Services and Collaborations
Pharma Services and Collaborations SEP 2023 17
Slide 18: Pharma Services & Collaboration strategy continues to make strong progress
Biovica’s Pharma Services & Collaboration strategy continues to make strong progress with new broad agreements signed during Q1 FY23/24 The Pharma Services & Collaborations Continuum 1. TESA 2. MSA 3. CDx Collaboration 4. CDx Product Technical Evaluation Master Service Agreement CDx Development Coll
Slide 19: Pharma Services revenue increase of +200% in Q1
Revenues in the Pharma Services and Collaboration business saw a Q1 increase of +200% from FY22/23 to FY23/24 FY21/22 FY22/23 FY23/24 Status • Q1 revenue: Revenue distribution: Revenue distribution: • +200% up from FY 22/23 • 90% TESA and Kit Supply • 52% TESA and Kit Supply • 10% TKa Testing Servic
Slide 20: Q1 Financial update
Q1 Financial update 20
Slide 21: Net Revenue Q1 2023/2024
Net Revenue Q1 2023/2024 Accumulated Net Sales SEK 000 4 000 • Net sales for the period May 2023- July 2023 was 3 500 SEK 1 754 (545) thousand, an increase with >200 % 3 000 vs same period last year 2 500 • Sales were coming from customers in the research 2 000 and pharma collaboration area where Di
Slide 22: Cash Position & Headcount
Cash Position & Headcount Cash SEK Millions 160 140 • The closing amount for cash & cash 120 equivalents end of July 2023 was SEK 76 (72) 100 80 million. 60 40 20 - Q1 Q2 Q3 Q4 Cash 2022/2023 Cash 2023/2024 Operating Cash flow SEK Millions development last 4 quarters Q1 23/24 Q4 22/23 Q3 22/23 Q2 22
Slide 23: Summary & Q&A
Summary & Q&A 23
Slide 24: Summary & Milestones
Summary & Milestones Measures cell proliferation from a simple blood sample Upcoming Milestones: DiviTum® TKa addresses an important clinical unmet need US milestones 2023: CLIA Lab Certification ✓, PLA Code & agreements with DiviTum® TKa is supported by cancer KOL’s and scientific payers & US hospi
Biovica International — Q1 2024 Earnings Presentation on 6ix